ProShares UltraShort NASDAQ Biotechnology
9 hedge funds and large institutions have $1.54M invested in ProShares UltraShort NASDAQ Biotechnology in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1.04% less ownership
Funds ownership: 2.59% → 1.55% (-1%)
18% less funds holding
Funds holding: 11 → 9 (-2)
54% less capital invested
Capital invested by funds: $3.34M → $1.54M (-$1.8M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$525K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$276K |
| 3 |
LC
Lindbrook Capital
Calabasas,
California
|
+$87.5K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$14.2K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
+$3.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$655K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$478K |
| 3 |
HF
HRT Financial
New York
|
-$275K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$214K |
| 5 |
Morgan Stanley
New York
|
-$68.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WP
1
WealthSource Partners
San Luis Obispo,
California
| $555K | +$525K | +6,750 | +360% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $334K | +$276K | +3,553 | +216% |
|
|
3
Citadel Advisors
Miami,
Florida
| $259K | -$214K | -2,750 | -40% |
|
|
HF
4
HRT Financial
New York
| $219K | -$275K | -3,538 | -51% |
|
|
LC
5
Lindbrook Capital
Calabasas,
California
| $72K | +$87.5K | +1,125 | New |
|
|
6
Simplex Trading
Chicago,
Illinois
| $70K | +$14.2K | +183 | +20% |
|
|
CG
7
Cutler Group
San Francisco,
California
| $19K | +$3.89K | +50 | +20% |
|
|
8
Morgan Stanley
New York
| $5K | -$68.5K | -880 | -92% |
|
9
Citigroup
New York
| $3K | – | – | – |
|
|
10
Jane Street
New York
| – | -$655K | -5,807 | Closed |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$478K | -4,223 | Closed |
|
12
UBS Group
Zurich,
Switzerland
| – | -$7K | -61 | Closed |
|
BIS Hedge Fund Activity: Q2 2020 in Review
9 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2020, worth a combined $1.54M — down 54% from $3.34M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BIS and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was WealthSource Partners, adding an estimated $525K. The largest seller was Jane Street, exiting entirely with an estimated $655K sold.
- 9 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2020, down from 11 in Q1 2020.
- Funds reported $1.54M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2020, down 54% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2020 and 3 closed out, a net change of -2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2020 was WealthSource Partners, an estimated $525K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2020 was Jane Street, an estimated $655K sold.
Based on aggregated 13F filings for Q2 2020.